EP1071325A4 - Compositions and methods for antigen-specific vaccination - Google Patents

Compositions and methods for antigen-specific vaccination

Info

Publication number
EP1071325A4
EP1071325A4 EP99913979A EP99913979A EP1071325A4 EP 1071325 A4 EP1071325 A4 EP 1071325A4 EP 99913979 A EP99913979 A EP 99913979A EP 99913979 A EP99913979 A EP 99913979A EP 1071325 A4 EP1071325 A4 EP 1071325A4
Authority
EP
European Patent Office
Prior art keywords
antigen
compositions
methods
specific vaccination
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99913979A
Other languages
German (de)
French (fr)
Other versions
EP1071325A1 (en
Inventor
Charles A Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1071325A1 publication Critical patent/EP1071325A1/en
Publication of EP1071325A4 publication Critical patent/EP1071325A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP99913979A 1998-03-20 1999-03-19 Compositions and methods for antigen-specific vaccination Withdrawn EP1071325A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7889098P 1998-03-20 1998-03-20
US78890P 1998-03-20
PCT/US1999/006034 WO1999046988A1 (en) 1998-03-20 1999-03-19 Compositions and methods for antigen-specific vaccination

Publications (2)

Publication Number Publication Date
EP1071325A1 EP1071325A1 (en) 2001-01-31
EP1071325A4 true EP1071325A4 (en) 2004-12-22

Family

ID=22146831

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99913979A Withdrawn EP1071325A4 (en) 1998-03-20 1999-03-19 Compositions and methods for antigen-specific vaccination

Country Status (5)

Country Link
EP (1) EP1071325A4 (en)
JP (1) JP2002506794A (en)
AU (1) AU759765B2 (en)
CA (1) CA2323232A1 (en)
WO (1) WO1999046988A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
CA2721011A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MORTARINI R ET AL: "Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.", CANCER RESEARCH. 15 DEC 1997, vol. 57, no. 24, 15 December 1997 (1997-12-15), pages 5534 - 5541, XP002302193, ISSN: 0008-5472 *
NESTLE F O ET AL: "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 3, March 1998 (1998-03-01), pages 328 - 332, XP002122868, ISSN: 1078-8956 *
REEVES M E ET AL: "RETROVIRAL TRANSDUCTION OF HUMAN DENDRITIC CELLS WITH A TUMOR-ASSOCIATED ANTIGEN GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 24, 15 December 1996 (1996-12-15), pages 5672 - 5677, XP002032192, ISSN: 0008-5472 *
ROSENBERG S A ET AL: "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.", NATURE MEDICINE. MAR 1998, vol. 4, no. 3, March 1998 (1998-03-01), pages 321 - 327, XP002091661, ISSN: 1078-8956 *
See also references of WO9946988A1 *
SPECHT JENNIFER M ET AL: "Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 1997, pages 1213 - 1221, XP002148420, ISSN: 0022-1007 *
YONGHONG WAN ET AL: "DENDRITIC CELLS TRANSDUCED WITH AN ADENOVIRAL VECTOR ENCODING A MODEL TUMOR-ASSOCIATED ANTIGEN FOR TUMOR VACCINATION", HUMAN GENE THERAPY, XX, XX, vol. 8, no. 11, 20 July 1997 (1997-07-20), pages 1355 - 1363, XP000877349, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
JP2002506794A (en) 2002-03-05
EP1071325A1 (en) 2001-01-31
CA2323232A1 (en) 1999-09-23
AU759765B2 (en) 2003-05-01
AU3193499A (en) 1999-10-11
WO1999046988A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
HK1039782A1 (en) Compositions and methods for wt1 specific immunotherapy
EP1176948A4 (en) Anti-nausea compositions and methods
IL137999A0 (en) Vaccine compositions
ZA978868B (en) Vaccine composition
GB2348808B (en) Methods and compositions for desensitisation
PL343429A1 (en) Combined vaccine compositions
HUP0101804A3 (en) Adjuvant composition and methods for its use
IL136454A0 (en) Compositions and methods for inducing gene expression
HUP0301394A3 (en) Methods and composition for oral vaccination
HUP0003745A3 (en) Methods and compositions for inducing tumor-specific cytotoxicity
EP1056456A4 (en) R-lansoprazole compositions and methods
PL331424A1 (en) Antipaludian vaccine composition
IL145891A0 (en) Methods and compositions for modulating an immune response
ZA979984B (en) Vaccine composition
EP1056457A4 (en) S-lansoprazole compositions and methods
EP1075184A4 (en) Compositions and methods for active vaccination
EP1073333A4 (en) S-rabeprazole compositions and methods
GB9801870D0 (en) Vaccine composition
EP1071325A4 (en) Compositions and methods for antigen-specific vaccination
AU8513698A (en) Methods and compositions for designing vaccines
EP1073332A4 (en) R-rabeprazole compositions and methods
GB9614618D0 (en) Vaccine compositions
IL139538A0 (en) Compositions and method for immunizing poultry
GB9921747D0 (en) Compositions and methods
GB9928549D0 (en) Compositions and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20041109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060530